These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20960486)

  • 1. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease.
    Meppelink AM; Nyman R; van Laar T; Drent M; Prins T; Leenders KL
    Mov Disord; 2011 Feb; 26(2):331-4. PubMed ID: 20960486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
    Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease.
    van Laar T; Nyholm D; Nyman R
    Acta Neurol Scand; 2016 Mar; 133(3):208-15. PubMed ID: 26213103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
    Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
    Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease.
    Nyman R; Lundgren D; Nyholm D
    J Vasc Interv Radiol; 2009 Apr; 20(4):500-5. PubMed ID: 19216094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Continuous treatment with levodopa of Parkinson disease].
    Lundqvist C; Nystedt T; Reiertsen O; Grotli R; Beiske AG
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2638-40. PubMed ID: 16215609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experience with continuous levodopa enteral infusion (Duodopa(®)) in patients with advanced Parkinson's disease in a secondary level hospital].
    Santos-García D; Macías M; Llaneza M; Fuster-Sanjurjo L; Echarri-Piudo A; Belmonte S; Blanco S
    Neurologia; 2010; 25(9):536-43. PubMed ID: 21093702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
    Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study.
    Zibetti M; Merola A; Ricchi V; Marchisio A; Artusi CA; Rizzi L; Montanaro E; Reggio D; De Angelis C; Rizzone M; Lopiano L
    J Neurol; 2013 Jan; 260(1):105-14. PubMed ID: 22772358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Duodopa
    Ciurleo R; Corallo F; Bonanno L; Lo Buono V; Di Lorenzo G; Versaci R; Allone C; Palmeri R; Bramanti P; Marino S
    J Neurol; 2018 Sep; 265(9):2005-2014. PubMed ID: 29951701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
    Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
    Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
    Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duodopa infusion treatment: a point of view from the gastroenterologist.
    Negreanu L; Popescu BO; Babiuc RD; Ene A; Bajenaru OA; Smarandache GC
    J Gastrointestin Liver Dis; 2011 Sep; 20(3):325-7. PubMed ID: 21961105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.